Guidelines| Volume 54, ISSUE 3, P309-315, March 2022

Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus

Published:December 02, 2021DOI:


      Background and aims

      Patients with inflammatory bowel diseases (IBD) are exposed to drug-related nephrotoxicity and kidney-related extra-intestinal manifestations (EIMs). Patients should be monitored but guidance is lacking in current international recommendations. The objective of the Kidney Function Monitoring in Inflammatory Bowel Disease (MONITORED) initiative was to achieve an expert consensus about monitoring kidney function in IBD.


      A literature review was first conducted. Then, an expert consensus meeting, involving 28 attendees representing French-speaking gastroenterologists and nephrologists, was held as part of an academic initiative on May 28, 2021. An anonymous Delphi process was used to discuss and vote on statements. Agreement was defined as at least 75% of participants voting for any one statement.


      Experts reached consensus on 11 criteria for referral to the nephrologist. Concerning kidney function monitoring, participants unanimously validated the use of serum creatinine with estimation of the glomerular filtration rate via the MDRD or CKD-EPI equations. A blood ionogram and a urine sample with measurement of a protein-to-creatinine ratio were also broadly agreed validated. Experts recommended performing this monitoring at IBD diagnosis, prior introducing a new treatment, and annually for EIMs screening and evaluation of treatment tolerance. An evaluation 3 months after starting mesalamine and then every 6 months was felt necessary, while for biologics an annually monitoring was deemed sufficient.


      The MONITORED consensus proposed guidelines on how to monitor kidney function in IBD. These recommendations should be considered in clinical practice to preserve kidney function and ensure the best approach to our patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Torres J.
        • Mehandru S.
        • Colombel J.-F.
        • Peyrin-Biroulet L.
        Crohn's disease.
        Lancet Lond Engl. 2017; 389: 1741-1755
        • Ungaro R.
        • Mehandru S.
        • Allen P.B.
        • Peyrin-Biroulet L.
        • Colombel J.-F.
        Ulcerative colitis.
        Lancet Lond Engl. 2017; 389: 1756-1770
        • Lasch K.
        • Liu S.
        • Ursos L.
        • et al.
        Gastroenterologists’ Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey.
        Adv Ther. 2016; 33: 1715-1727
        • Harbord M.
        • Eliakim R.
        • Bettenworth D.
        • et al.
        Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management.
        J Crohns Colitis. 2017; 11: 769-784
        • Loftus E.V.
        • Kane S.V.
        • Bjorkman D.
        Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
        Aliment Pharmacol Ther. 2004; 19: 179-189
        • Corrigan G.
        • Stevens P.E.
        Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
        Aliment Pharmacol Ther. 2000; 14: 1-6
        • Gisbert J.P.
        • González-Lama Y.
        • Maté J.
        5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.
        Inflamm Bowel Dis. 2007; 13: 629-638
        • Heap G.A.
        • So K.
        • Weedon M.
        • et al.
        Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced Nephrotoxicity in inflammatory bowel disease.
        J Crohns Colitis. 2016; 10: 149-158
        • Haas M.
        • Shetye K.R.
        Acute renal failure in a 53-year-old woman with Crohn's disease treated with 5-aminosalicylic acid.
        Am J Kidney Dis Off J Natl Kidney Found. 2001; 38: 205-209
        • Frandsen N.E.
        • Saugmann S.
        • Marcussen N.
        Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
        Nephron. 2002; 92: 200-202
        • Gupta A.
        • Pendyala P.
        • Arora P.
        • Sitrin M.D.
        Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
        J Clin Gastroenterol. 2011; 45: e30-e33
        • Sato T.
        • Kawasaki Y.
        • Ito A.
        • et al.
        Infliximab-Induced Tubulointerstitial Nephritis with Image Findings of Striated Nephrogram in Crohn's Disease.
        Tohoku J Exp Med. 2018; 245: 149-152
        • Dumitrescu G.
        • Dahan K.
        • Treton X.
        • Corcos O.
        • Bouhnik Y.
        • Stefanescu C.
        Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis.
        J Gastrointest Liver Dis JGLD. 2015; 24: 249-251
        • Bailly E.
        • Von Tokarski F.
        • Beau-Salinas F.
        • et al.
        Interstitial nephritis secondary to vedolizumab treatment in crohn disease and safe rechallenge using steroids: a case report.
        Am J Kidney Dis Off J Natl Kidney Found. 2018; 71: 142-145
        • Oikonomou K.
        • Kapsoritakis A.
        • Eleftheriadis T.
        • Stefanidis I.
        • Potamianos S.
        Renal manifestations and complications of inflammatory bowel disease.
        Inflamm Bowel Dis. 2011; 17: 1034-1045
        • Ott C.
        • Schölmerich J.
        Extraintestinal manifestations and complications in IBD.
        Nat Rev Gastroenterol Hepatol. 2013; 10: 585-595
        • Corica D.
        • Romano C.
        Renal Involvement in Inflammatory Bowel Diseases.
        J Crohns Colitis. 2016; 10: 226-235
        • Dignass A.
        • Lindsay J.O.
        • Sturm A.
        • et al.
        Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.
        J Crohns Colitis. 2012; 6: 991-1030
        • Travis S.P.L.
        • Stange E.F.
        • Lémann M.
        • et al.
        European evidence-based Consensus on the management of ulcerative colitis: Current management.
        J Crohns Colitis. 2008; 2: 24-62
        • Kornbluth A.
        • Sachar D.B.
        • Practice Parameters Committee of the American College of Gastroenterology
        Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.
        Am J Gastroenterol. 2010; 105 (quiz 524): 501-523
        • Ko C.W.
        • Singh S.
        • Feuerstein J.D.
        • et al.
        AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis.
        Gastroenterology. 2019; 156: 748-764
        • Singh S.
        • Feuerstein J.D.
        • Binion D.G.
        • Tremaine W.J.
        AGA technical review on the management of mild-to-moderate ulcerative colitis.
        Gastroenterology. 2019; 156 (e29): 769-808
        • Bressler B.
        • Marshall J.K.
        • Bernstein C.N.
        • et al.
        Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
        Gastroenterology. 2015; 148 (e3): 1035-1058
        • Lamb C.A.
        • Kennedy N.A.
        • Raine T.
        • et al.
        British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
        Gut. 2019; 68 (s1-s106)
        • Biancone L.
        • Annese V.
        • Ardizzone S.
        • et al.
        Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
        Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2017; 49: 338-358
      1. GETAID. Dérivés aminosalicylés : Rowasa®, Fivasa®, Pentasa®, Dipentum®, Salazopyrine®, Quadrasa®. 2019.

        • Guillo L.
        • D'Amico F.
        • Achit H.
        • et al.
        Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know.
        Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2021; 53: 691-696
        • Kidney Disease: Improving Global, Outcomes (KDIGO) Acute Kidney Injury Work Group
        KDIGO clinical practice guideline for acute kidney injury.
        Kidney inter. 2012; 2 (Suppl.): 1-138
        • Kidney Disease: Improving Global
        Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.
        Kidney Inter. 2013; 3 (Suppl.): 1-150
        • Delanaye P.
        • Jager K.J.
        • Bökenkamp A.
        • et al.
        CKD: A Call for an Age-Adapted Definition.
        J Am Soc Nephrol JASN. 2019; 30: 1785-1805
      2. Food and Drug Administration. Mesalamine prescribing information as of 05/2010. Accessed August 11, 2020.

      3. Food and Drug Administration. Mesalamine prescribing information as of 07/2019. Accessed August 11, 2020.

        • Bruzzese V.
        • Lorenzetti R.
        • Rosa M.
        • et al.
        IgA nephropathy onset in a Crohn's disease patient treated with Adalimumab.
        Minerva Gastroenterol Dietol. 2016; 62: 223-224
        • Leong J.
        • Fung-Liu B.
        A case report of nephrotic syndrome due to intake of certolizumab pegol in a patient with Crohn's disease.
        Am J Gastroenterol. 2010; 105: 234
        • Ota M.
        • Iwai H.
        • Imai K.
        • et al.
        Acute tubulointerstitial nephritis associated with infliximab in a patient with Crohn's disease.
        Intern Med Tokyo Jpn. 2016; 55: 1367-1370
        • Bhagat Singh A.K.
        • Jeyaruban A.S.
        • Wilson G.J.
        • Ranganathan D.
        Adalimumab-induced IgA nephropathy.
        BMJ Case Rep. 2019; 12e226442
        • Jairath V.
        • Hokkanen S.R.K.
        • Guizzetti L.
        • Boxall N.
        • Campbell-Hill S.
        • Patel H.
        No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study.
        Aliment Pharmacol Ther. 2019; 50: 416-424